Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

e dose escalation trial in patients with advanced hematologic malignancies. Patients are dosed for 21 days on a 28-day cycle. A minimum of three patients are treated at each dose level. The study is divided into two arms, one for treatment of leukemia patients and the other for treatment of patients with lymphoma and myeloma. For the leukemia arm of the study, patients are currently being treated at the tenth dose level, 250 mg twice daily. For the lymphoma and myeloma arm, patients are currently being treated at the sixth dose level, 150 mg twice daily.

Positive Safety and Tolerability Data: The goal of the Phase I study is to establish the safety, tolerability and pharmacokinetics of the drug. Thus far, 104 one-month cycles of AVN944 have been initiated in 46 patients and the compound is well tolerated. Pharmacokinetics measurements indicate dose proportional plasma levels of AVN944 during treatment and sustained plasma concentrations at the dose levels tested thus far.

Early Activity Indicators: This Phase I study is designed to evaluate several pharmacodynamic and efficacy-related endpoints. Upon entering the trial, all patients have refractory, progressive disease and have failed all prior therapies. Thus far, 18 of 39 evaluable patients (46%) showed stabilized disease after one cycle of treatment with AVN944. These include patients with both leukemia and multiple myeloma. Patients who have achieved stable disease following completion of a one-month treatment cycle with AVN944, as determined by the clinical investigator, may be advanced to a subsequent cycle.

In the multiple myeloma cohort 60% of the patients have achieved stabilized disease after one month. Two of these patients completed five months of treatment and two others completed one full year of treatment. One AML patient has completed 8 monthly cycles of treatment.

Positive Dose Dependent Biomarker Data: The AvalonRx(R) platform has identified selected biomarkers from pati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:11/26/2014)... FRANCISCO , Nov. 25, 2014  goBalto, Inc., ... has been recognized as a winner of Red Herring,s ... a Global Top 100 North America award in 2013, ... international technology landscape. Red Herring,s Top 100 ... identifying promising new companies and entrepreneurs. Red Herring editors ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
... CONCORD, N.H., Oct. 5 A new statewide prescription assistance ... New Hampshire Rx Card will offer savings of up to ... across the country. All New Hampshire residents are eligible to ... can download a "FREE" card by visiting www.nhrxcard.com ...
... 5 BioWa, Inc. announced today that it ... Co. Ltd. (Otsuka) to provide Otsuka with access ... development and commercialization of their antibody therapeutics with ... Japanese pharmaceutical POTELLIGENT® License was initiated in May, ...
Cached Medicine Technology:New Hampshire Rx Card Launching Statewide 2BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... 2014 Nearly 1,100 Risperdal lawsuits ... a consolidated litigation now underway in Pennsylvania state ... recently updated in the Philadelphia Court of Common ... proceeding, all of which involve a drug approved ... conditions. Many of the cases in this proceeding ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
(Date:11/27/2014)... Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals can ... a gluten-free diet, an expert says. Many traditional ... and cranberry sauce -- are gluten-free, but "when it ... need to be considered," Dr. Anca Safta, director of ... Forest Baptist Medical Center in North Carolina, said in ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... a 50 meter radius of the venues of the ... said 27 medical response teams would be,deployed in all ... beginning,Sunday., ,Duque said the ban is part of ... the athletes as well as of the spectators., ...
... The age limit of Indians becoming sexually active is ... people in 15-19 years age, sexually transmitted infections, including ... that half the HIV infected people worldwide are between ... an official statement released today, the spokesperson of Christian ...
... An article published in the October issue of the journal Nutrition ... could end the search for a drug to beat prostate cancer.// ... cancer cells to commit "suicide." The researchers report that the drug ... growth plus it also caused "apoptosis". This is the natural process ...
... virus is conducted in Indonesia in order to eradicate ... 290 polio cases in the last six months.// ... of vaccination program this month end and they have ... provided vaccination to about 23.6 million children’s in Indonesia. ...
... innumerable benefits of fish oil for improvement of health ... might be good enough even in the prevention of ... ,Multiple Sclerosis is a disease characterized by ... disease is a significant problem for the patients. It ...
... Minister Dr Anbumani Ramadoss party was the first to raise ... Now he is trying to do a balancing act to diffuse ... need many more Khushboos to talk about safe sex to the ... marriage.’’, ,The minister said that his department had engaged ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: